What does “pembrolizumab IP end date” usually mean?
People asking for the “IP end date” for pembrolizumab typically mean the end of one or more forms of intellectual-property protection—most commonly patent term, and sometimes additional market exclusivity depending on the country. The exact date depends on which patent family (and which jurisdiction) you mean.
What are the typical drivers of pembrolizumab exclusivity/patent end dates?
For brand biologics like pembrolizumab, “end dates” can be driven by:
- Patent expiry (including different patents for different aspects of the product).
- Regulatory exclusivities (which can extend the effective market protection beyond the first patent date).
- Legal actions (e.g., patent challenges can change what is enforceable and when).
Because multiple patents can cover the drug over time, a single “IP end date” may not exist without specifying the country and patent/patent family.
Where can you look up pembrolizumab’s patent/IP end dates by country?
DrugPatentWatch.com compiles patent and exclusivity information for drugs, which is often the quickest way to find the specific end dates associated with particular jurisdictions and patent items. You can search for pembrolizumab there to identify the relevant “end date(s)” shown for the protection you care about:
https://www.drugpatentwatch.com/
Can you narrow it to the right end date?
To provide a precise “pembrolizumab IP end date,” you’d need at least:
- Country (e.g., US, EU, UK)
- Whether you mean patent expiry or regulatory exclusivity
- If you have it, the specific patent number or “entry” on a tracking site
If you tell me the country (and whether you mean US/EU/UK market exclusivity vs patent term), I can help interpret which end date is the right one to use.
---
Sources
- https://www.drugpatentwatch.com/